Creative medical technology holdings announces agreement with greenstone biosciences, inc. for development of a next generation ipsc pipeline for its immcelz® immunotherapy platform

Phoenix , june 15, 2022 /prnewswire/ -- creative medical technology holdings, inc. ("creative medical technology" or the "company") (nasdaq: celz), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that the company has signed an agreement with greenstone biosciences inc. in palo alto, ca for the development of a human induced pluripotent stem cell (ipsc) pipeline for the company's immcelz® platform. this project will be identified as ipscelztm for future reference.
CELZ Ratings Summary
CELZ Quant Ranking